Revisiting the role of gut wall in the fate of orally administered drugs: Why now and to what effect?

about

Revisiting the role of gut wall in the fate of orally administered drugs: Why now and to what effect?

Item

http://www.wikidata.org/entity/Q54178337

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Revisiting the role of gut wal ...... s: Why now and to what effect?

@en

Revisiting the role of gut wal ...... s: Why now and to what effect?

@nl

type

Item

label

Revisiting the role of gut wal ...... s: Why now and to what effect?

@en

Revisiting the role of gut wal ...... s: Why now and to what effect?

@nl

prefLabel

Revisiting the role of gut wal ...... s: Why now and to what effect?

@en

Revisiting the role of gut wal ...... s: Why now and to what effect?

@nl

P1476

Revisiting the role of gut wal ...... s: Why now and to what effect?

@en

P2093

Amin Rostami-Hodjegan

http://www.w3.org/2001/XMLSchema#string

Ikumi Tamai

http://www.w3.org/2001/XMLSchema#string

K Sandy Pang

http://www.w3.org/2001/XMLSchema#string

P2860

Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance

Prediction of intestinal first-pass drug metabolism.

Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series).

PBPK modeling of intestinal and liver enzymes and transporters in drug absorption and sequential metabolism.

PBPK models for the prediction of in vivo performance of oral dosage forms.

OATP transporter-mediated drug absorption and interaction.

Caco-2 cells - expression, regulation and function of drug transporters compared with human jejunal tissue.

IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.

IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.

P-gp activity and inhibition in the different regions of human intestine ex vivo.

P304

87-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1002/BDD.2071

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28317174

http://www.w3.org/2001/XMLSchema#string